Progress of related gene polymorphism of 5-fluorouracil-based chemotherapy efficacy and adverse reactions in colorectal cancer
10.3760/cma.j.issn.1006-9801.2019.09.017
- VernacularTitle: 基于5-氟尿嘧啶的直肠癌化疗疗效和不良反应的相关基因多态性研究进展
- Author:
Tingting LI
1
;
Ying XIE
1
;
Linhai HE
2
;
Zhen WANG
2
Author Information
1. Department of Clinical Pharmacy, the People's Hospital of Jinghong City of Xishuangbanna Dai Nationality Autonomous Prefecture of Yunnan Province, Jinghong 666100, China
2. Department of General Surgery, the People's Hospital of Jinghong City of Xishuangbanna Dai Nationality Autonomous Prefecture of Yunnan Province, Jinghong 666100, China
- Publication Type:Review
- Keywords:
5-fluorouracil;
Colorectal neoplasms;
Adverse reactions;
Gene polymorphism
- From:
Cancer Research and Clinic
2019;31(9):644-648
- CountryChina
- Language:Chinese
-
Abstract:
5-fluorouracil (5-Fu) has been the basic drug in the first-line chemotherapy for colorectal cancer so far. A large number of studies have focused on the discovery of gene polymorphism sites for predicting the efficacy or adverse reactions of 5-Fu. Multiple polymorphic sites of genes such as TYMS, DPYD, and MTHFR may play a role in it. However, no consistent conclusion has been reached over the effect of same polymorphic site on the therapeutic outcome. The application of whole genome sequencing and multi-gene joint analysis may carry out more comprehensive and in-depth researches in the future. This paper reviews the progress of related gene polymorphism of 5-Fu-based chemotherapy efficacy and adverse reactions in colorectal cancer.
